Bringing you live news and features since 2006 

ETFMG adds biotech fund to thematic ETF offering


Thematic ETF issuer ETFMG has launched the ETFMG Treatments, Testing and Advancements ETF (GERM), which seeks to answer investor demand for direct exposure to the biotech companies directly engaged in the testing and treatments of infectious diseases. The first-to-market methodology behind the Fund focuses on the advancements in the infectious disease sub-sector of biotech with targeted exposure to US-listed companies at the forefront of R&D, vaccines, therapies and testing technologies.

GERM provides access to both established providers as well as the “unsung heroes” of the biotech and life sciences market. The frequency and diversity of disease outbreaks, similar to COVID-19, have grown steadily for the past 30 years.

“Our global health depends a great deal on innovation and discovery that will address how to prevent further infection with enhanced immune therapies or vaccines,” says Reynold A Panettieri, Jr, MD, Professor of Medicine, Vice Chancellor for Translational Medicine and Science at Rutgers University, and Director of the Institute for Translational Medicine and Science. “GERM offers a unique approach that embraces cutting-edge technologies through cooperativity among Big/Small Pharma and biotech that can nimbly leverage discoveries and translate them into commercialised and impactful assets.”

“GERM represents an investment theme that is much more than topical, it provides unique exposure to a previously underrepresented growth sector within biotech. We are excited to bring this product to US investors,” says Sam Masucci, CEO and Founder of ETFMG.

Latest News

HSBC Asset Management’s (HSBC AM) ETF and Indexing business has passed USD100 billion in assets under management (AUM), reflecting its..
Amundi’s ETF Market Flows Analysis for April reveals that investors added EUR54.1 billion to global ETFs in April with equities..
VanEck has reached USD10 billion in assets under management in Europe for the first time in April 2024...
Global index revenues increased 9.3 per cent in 2023, totalling a record USD5.8 billion, according to a benchmark study published..

Related Articles

Dan Miller, IQ-EQ
With just over a week to go till T+1 settlement begins in North America, Canada and Mexico, time is of...
Emily Spurling, Nasdaq
Last October’s ETF Express US Awards 2023 found Nasdaq winning Best Index Provider – ESG ETFs and Best Index Provider...
Vinit Srivistava, MerQube
Index provider, MerQube, launched in 2019, with the aim of providing a “technology-driven answer to the most complex, rules-based investment...
Sean O' Hara
Pacer ETFs has announced the launch of three Cash Cows UCITS ETFs. The firm writes that this will give European...
Subscribe to the ETF Express newsletter

Subscribe for access to our weekly newsletter, newsletter archive, updates on the site and exclusive email content.

Marketing by